RX Biosyent Inc

BioSyent Inc. (“BioSyent”) (TSX Venture:RX) will be reporting its financial results for the three and six months ended June 30, 2017 on Wednesday, August 16, 2017 at 8:00am (ET).  A presentation on the Company’s second quarter and first half 2017 results by Mr. René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients.  BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 14,476,353 shares issued and outstanding.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
Tel: (905) 206-0013
E-Mail: investors@biosyent.com
Web: www.biosyent.com